Amneal Pharmaceuticals (AMRX) FY Conference June 10, 2025 10:40 AM ET Speaker0 Okay. Great. Well, thank you everyone for joining us today. My name is Matt Delatorre, and I'm the generics pharma analyst here at GS. And we're we're very pleased to have Amneal Pharmaceuticals with us for this session with Sharag Patel, cofounder and co CEO, and Tassos Konidaris, the chief financial officer. Great. So maybe maybe just to get started, you know, how about just level set us on where Amneal is headed from kind of a ...

Stevanato Group (STVN) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Jeff there we go. Hi. Good morning. Dave Windley with Jefferies Healthcare Equity Research. Appreciate your attendance and and interest in our conference twenty twenty five. We are on kind of the homestretch here on Thursday. Our presenting company for this session is Stevanato Group. Here to present for them is the company's CEO, Franco Sveinato. So he has just a few slides and is going to give some prepared remarks to kick off and t ...

Financial Data and Key Metrics Changes - The company has seen significant growth in its integrated delivery network (IDN) sales, which were up 12 times from 2024 to 2023, indicating a strong market acceptance of its product [21] - The redesign of Medicare Part D is expected to provide a significant tailwind, with patients now having a $2,000 cap on out-of-pocket expenses, which is anticipated to drive higher fill rates and net sales [42][45] Business Line Data and Key Metrics Changes - The company’s product, Furosex, is designed to deliver 100% bioavailable furosemide, which is equivalent to the IV treatment in hospitals, allowing patients to manage their condition at home [6][14] - The approval for chronic kidney disease (CKD) indication is expected to expand the total addressable market (TAM), with approximately 700,000 patients having CKD without heart failure, and many patients suffering from both conditions [27][29] Market Data and Key Metrics Changes - The company is focusing on integrated delivery networks (IDNs) where physicians are financially aligned with hospitals, which enhances the value proposition of Furosex [19] - There is a noted difference in how various IDNs operate, with larger systems like Kaiser and the VA being more closed and structured, while smaller IDNs may require tailored protocols for best practices [25][26] Company Strategy and Development Direction - The company aims to capture the value proposition of its product by focusing on early intervention in heart failure patients to prevent hospitalizations [10][17] - The introduction of an auto-injector is expected to simplify the treatment process, reduce costs of goods sold (COGS) by 70%, and extend intellectual property protection until 2040 [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the impact of the Medicare redesign, which is expected to facilitate patient access to the drug and drive sales growth [39][46] - The expansion of the sales force is anticipated to take time to show results, but early indicators suggest positive trends in sales as more representatives engage with healthcare providers [54] Other Important Information - The company has developed internal protocols for IDNs to share best practices, which is crucial for smaller networks that may lack established guidelines [24][26] - The management highlighted the importance of addressing the needs of patients who are discharged from hospitals with residual congestion, as this presents an opportunity for Furosex to prevent readmissions [15][17] Q&A Session Summary Question: How does the company see the balance between preventing hospitalizations and reducing length of stay? - The company aims to intervene early when patients first show signs of worsening heart failure, thus preventing the need for hospitalization [10][11] Question: Are hospitals with higher readmission rates embracing Furosex? - There is a need for education among hospital staff, particularly among cardiologists who may not be fully aware of the benefits of Furosex [18] Question: How does the CKD indication expand opportunities? - The CKD indication opens up a new market segment, particularly for patients with cardiorenal disease, which is expected to drive growth [27][29] Question: What are the expected impacts of the Medicare Part D redesign? - The redesign is anticipated to lower out-of-pocket costs for patients, thereby increasing fill rates and driving sales growth [39][45] Question: How does the auto-injector fit into the company's strategy? - The auto-injector is expected to simplify the treatment process and significantly reduce costs, while also appealing to a broader patient base [49][51]

Summary of Jabil (JBL) FY Conference Call - May 13, 2025 Company Overview - **Company**: Jabil (JBL) - **Industry**: Electronics Manufacturing Services (EMS) Key Points and Arguments Macro Economic Concerns - There is a sense of relief among customers regarding recession fears, with the administration's efforts seen as effective in preventing a significant downturn [3][5][6] - Jabil's diversified portfolio across various end markets, including healthcare and digital commerce, positions the company well to manage through economic fluctuations [4][5] Supply Chain and Tariff Management - Jabil has regionalized its supply chain, producing in-country for local consumption, which mitigates risks associated with tariff volatility [7][8] - The company is not currently seeing significant shifts in business due to tariffs, as customers are cautious about the costs and risks of relocating operations [8] Capacity and Geographic Flexibility - Approximately 35% to 40% of Jabil's capacity is located in the Americas, with current utilization around 75-80%, indicating room for growth [16][18] - The company has recently opened a facility in St. Petersburg, Florida, and has the capability to expand in the U.S. and Mexico as needed [16][18] Margin Improvement Strategies - Jabil aims to increase its margin from 5.4% to 6% or 6.5% in the near future, driven by portfolio diversification, vertical integration, and operational efficiencies [22][23][24] - The company is focusing on higher-margin businesses and has made tuck-in acquisitions to enhance its service offerings [24][25] Growth in Cloud and Data Center Infrastructure - Jabil has increased its revenue guidance for the second half of the fiscal year by $1 billion, driven by strong demand from hyperscale customers and capital equipment business [28] - The company is confident in continued spending from cloud customers, viewing it as an "arms race" among hyperscalers [28][29] Automotive Sector Challenges - The automotive segment faces headwinds from tariffs and reduced demand for electric vehicles (EVs), but Jabil is diversifying its customer base and product offerings to mitigate risks [44][45] - The company has added new OEM customers in China, which is expected to provide growth opportunities in the EV space [46][48] Healthcare Market Opportunities - Jabil is significantly larger than its nearest competitor in the healthcare market and is focused on expanding its share of wallet through organic growth and acquisitions [56][57] - The company recently acquired Pharmaceutical International Incorporated, enhancing its capabilities in pharmaceutical delivery systems [58] Semiconductor Capital Equipment - Jabil's semiconductor capital equipment business is performing well, with strong growth driven by key customers like NVIDIA [62] - The company anticipates a cyclical recovery in the semiconductor industry within the next twelve months [63] Networking and Communications - The networking segment is experiencing slower growth due to exiting low-margin businesses, but there are positive trends in Ethernet and liquid cooling technologies [65][66] Digital Commerce Growth - Jabil is seeing growth in digital commerce, particularly in automation and robotics for retail environments, with expectations for continued expansion in this area [67][68] Future Outlook - Jabil's path to achieving higher margins is not solely dependent on revenue growth but also on optimizing product mix and operational efficiencies [69][70] - The company is well-positioned for future growth across various sectors, including healthcare, cloud infrastructure, and automotive, despite current economic challenges [49][50][56]

scPharmaceuticals (SCPH) 2025 Conference May 07, 2025 09:30 AM ET Speaker0 Everybody, thank you for joining us at the Citizens Life Science Conference. I'm Jason Butler. I'm one of the biopharma analysts here at Citizens. Excited to kick off this conference this week. Specifically excited to be joined by our first company SC Pharmaceuticals. SC Pharma is a company focused on the cardio renal space, is launching a product called Furosex. Had an exciting announcement just a few weeks ago with a label expansio ...

Amneal Pharmaceuticals (AMRX) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Anthony DiMeo - Head - IRChirag Patel - President and Co-Chief Executive OfficerChintu Patel - Co-Chief Executive OfficerTasos Konidaris - EVP & CFOLes Sulewski - VP - Biotech Equity ResearchChris Schott - Managing Director Conference Call Participants David Amsellem - Sr. Research Analyst Operator Good morning, and welcome to the Amneal Pharmaceuticals First Quarter twenty twenty five Earnings Call. I'd now li ...

Jabil (JBL) Q2 2025 Earnings Call March 20, 2025 08:30 AM ET Company Participants Adam Berry - Senior Vice President of Investor Relations & CommunicationsGreg Hebard - CFOMike Dastoor - Director & CEORuplu Bhattacharya - DirectorSamik Chatterjee - Executive DirectorDavid Vogt - Managing DirectorGeorge Wang - Vice PresidentMelissa Dailey Fairbanks - Vice President Conference Call Participants Mark Delaney - Stock Analyst Operator Greetings and welcome to Jabil's Second Quarter Fiscal Year twenty twenty five ...

Amneal Pharmaceuticals (AMRX) Q4 2024 Earnings Call February 28, 2025 08:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor RelationsChirag Patel - Co-Founder, Co-CEO, President & DirectorChintu Patel - Co-Founder, Co-CEO & DirectorTasos Konidaris - Executive Vice President, Chief Financial OfficerChris Schott - Managing DirectorJoe Renda - Senior VP & Chief Commercial Officer of SpecialtyLes Sulewski - VP - Biotech Equity ResearchJason Daly - Senior VP, Chief Legal Officer & Corporat ...